Merck's CEO said the $70 billion mid-2030s forecast for new medicines excludes upside from positive trial readouts and new assets like Terns and a PD-1/VEGF bispecific.
Merck CEO Robert Davis said its January forecast of $70 billion by the mid-2030s for its emerging portfolio of new medicines had not factored in the potential impact of positive clinical trial readouts and some other new assets, such as its Terns Pharma deal and an experimental PD-1/VEGF bispecific antibody drug.